As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Afgelopen vrijdag, op 16 mei werd de CEO van Novo Nordisk, Lars Fruergaard Jørgensen onverwacht ontslagen als CEO van het ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down as the company grapples with potential issues in the competitive obesity drug market. Market reactions suggest mixed feelings, ...

Novo Nordisk (NVO) stock falls as the company CEO Lars Fruergaard Jørgensen steps down after 8 years of leadership marked by ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...